Stay updated on Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The page now displays an updated “Revision” version number for the ClinicalTrials.gov interface (from v3.5.2 to v3.5.3). This represents a platform/version update rather than a modification to the trial record itself.
    Difference
    0.0%
    Check dated 2026-04-26T15:13:39.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2 and removed Revision: v3.5.0 in the history log.
    Difference
    0.0%
    Check dated 2026-04-19T12:44:28.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    36 days ago
    Change Detected
    Summary
    Added Revision: v3.5.0 and removed Revision: v3.4.3 from the page history.
    Difference
    0.0%
    Check dated 2026-03-21T08:47:03.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    A new revision entry, Revision: v3.4.3, was added and the previous Revision: v3.4.2 entry was removed.
    Difference
    0.0%
    Check dated 2026-03-06T21:00:32.000Z thumbnail image
  6. Check
    72 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.4.2, replacing the previous Revision: v3.4.1.
    Difference
    0.0%
    Check dated 2026-02-13T12:14:03.000Z thumbnail image
  7. Check
    80 days ago
    Change Detected
    Summary
    Revision: v3.4.1 was added and Revision: v3.4.0 was removed.
    Difference
    0.0%
    Check dated 2026-02-05T14:22:28.000Z thumbnail image

Stay in the know with updates to Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.